SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

Recruiting

Phase 2

Pregabalin, Duloxetine, PlaceboSPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

Sponsor:

University of Rochester

Code:

NCT06614322

Conditions

Painful Peripheral Neuropathy

Diabetic Peripheral Neuropathic Pain (DPN)

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Idiopathic Peripheral Neuropathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Pregabalin

Duloxetine

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-29. This information was provided to ClinicalTrials.gov by University of Rochester on 2026-04-23.